Serum zinc deficiency is a potential risk factor for the occurrence of levodopa-induced dyskinesia in drug-naïve Parkinson's disease.

Parkinson’s disease heavy metal levodopa-induced dyskinesia risk factors zinc

Journal

Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824

Informations de publication

Date de publication:
2023
Historique:
received: 24 08 2023
accepted: 23 10 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Since environmental factors, especially heavy metals, were highlighted in the pathogenesis of Parkinson's disease (PD), there are many epidemiologic studies regarding heavy metals and PD risk. However, longitudinal studies regarding the impacts of heavy metals on motor and nonmotor symptoms of PD are scarce. In the current study, we compared the serum levels of five heavy metals, such as zinc(Zn), copper(Cu), lead(Pb), mercury(Hg), and manganese(Mn), in 111 previously drug-naïve PD patients ( Zn deficiency was significantly higher in the PD with LID group than in the PD without LID group (79.58 ± 12.28 versus 88.16 ± 15.15 μg/L). Lower serum Zn levels were significantly correlated with age of onset, levodopa equivalent daily dose (LEDD) at 3 months, and Korean version of the Mini-Mental State Examination (K-MMSE) scores ( This study suggests that serum Zn deficiency might be a risk factor for LID in drug-naïve PD patients.

Sections du résumé

Background UNASSIGNED
Since environmental factors, especially heavy metals, were highlighted in the pathogenesis of Parkinson's disease (PD), there are many epidemiologic studies regarding heavy metals and PD risk. However, longitudinal studies regarding the impacts of heavy metals on motor and nonmotor symptoms of PD are scarce.
Methods UNASSIGNED
In the current study, we compared the serum levels of five heavy metals, such as zinc(Zn), copper(Cu), lead(Pb), mercury(Hg), and manganese(Mn), in 111 previously drug-naïve PD patients (
Results UNASSIGNED
Zn deficiency was significantly higher in the PD with LID group than in the PD without LID group (79.58 ± 12.28 versus 88.16 ± 15.15 μg/L). Lower serum Zn levels were significantly correlated with age of onset, levodopa equivalent daily dose (LEDD) at 3 months, and Korean version of the Mini-Mental State Examination (K-MMSE) scores (
Conclusion UNASSIGNED
This study suggests that serum Zn deficiency might be a risk factor for LID in drug-naïve PD patients.

Identifiants

pubmed: 38020782
doi: 10.3389/fnagi.2023.1282367
pmc: PMC10652755
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1282367

Informations de copyright

Copyright © 2023 Kim, Lee and Jang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Références

Front Aging Neurosci. 2023 Apr 27;15:1132907
pubmed: 37181629
Acta Otolaryngol Suppl. 2002;(546):116-21
pubmed: 12132608
J Nucl Med. 2012 Mar;53(3):399-406
pubmed: 22323779
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Front Neurol. 2018 Dec 20;9:1133
pubmed: 30619078
Sci Adv. 2020 Jul 3;6(27):
pubmed: 32937457
Int J Biol Macromol. 2022 Dec 1;222(Pt B):2878-2887
pubmed: 36252622
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Front Pharmacol. 2022 Apr 07;13:805388
pubmed: 35462934
Neuroepidemiology. 2010;34(1):18-24
pubmed: 19893325
Sci Rep. 2016 Feb 25;6:21850
pubmed: 26912464
Mol Cells. 2020 Apr 30;43(4):323-330
pubmed: 32274919
Mov Disord. 2020 Apr;35(4):662-671
pubmed: 31889341
Parkinsonism Relat Disord. 2002 Jun;8(5):297-309
pubmed: 15177059
JAMA. 2014 Apr 23-30;311(16):1670-83
pubmed: 24756517
J Neurochem. 2008 Jul;106(1):486-94
pubmed: 18410512
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Neurosci. 2016 Jun 15;36(24):6514-24
pubmed: 27307239
Mov Disord. 2022 Aug;37(8):1654-1662
pubmed: 35614551
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):141-3
pubmed: 14707325
Front Neurol. 2019 Mar 19;10:218
pubmed: 30941085
PLoS One. 2013 Dec 10;8(12):e83060
pubmed: 24340079
Parkinsonism Relat Disord. 2018 Oct;55:117-121
pubmed: 29891430
Nat Rev Neurosci. 2008 Sep;9(9):665-77
pubmed: 18714325
Arch Neurol. 2006 Feb;63(2):205-9
pubmed: 16476808
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946908
BMC Neurosci. 2019 May 22;20(1):23
pubmed: 31117957
J Hazard Mater. 2023 Apr 5;447:130779
pubmed: 36669416
Adv Neurotoxicol. 2017;1:119-130
pubmed: 30729219
Exp Suppl. 2012;101:133-64
pubmed: 22945569
J Altern Complement Med. 1999 Feb;5(1):57-64
pubmed: 10100031
Mov Disord. 2000 May;15(3):459-66
pubmed: 10830409
Biol Trace Elem Res. 2000 Jun;74(3):203-10
pubmed: 11055807
Nutrients. 2021 Nov 17;13(11):
pubmed: 34836369
Front Aging Neurosci. 2013 Jul 19;5:33
pubmed: 23882214
Neurology. 2014 May 6;82(18):1597-604
pubmed: 24719485
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):423-431
pubmed: 29075830
Biol Trace Elem Res. 2017 Sep;179(1):45-51
pubmed: 28160244
Front Chem. 2019 Mar 05;7:115
pubmed: 30891444
J Alzheimers Dis. 2020;76(4):1215-1242
pubmed: 32651318
J Biol Chem. 2001 Nov 23;276(47):44284-96
pubmed: 11553618
Neurobiol Dis. 2020 Feb;134:104681
pubmed: 31759136
J Neural Transm (Vienna). 2020 Feb;127(2):181-187
pubmed: 32025811
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S52-4
pubmed: 22166454
Postgrad Med J. 2007 Jun;83(980):384-8
pubmed: 17551069
Am J Epidemiol. 2023 Jul 7;192(7):1207-1223
pubmed: 37022311
Neurosci Lett. 2021 May 14;753:135873
pubmed: 33812934
Sci Rep. 2017 Jun 20;7(1):3902
pubmed: 28634347
Sci Rep. 2022 Jul 13;12(1):11898
pubmed: 35831343
N Am J Med Sci. 2014 Aug;6(8):370-6
pubmed: 25210669
Am J Alzheimers Dis Other Demen. 2010 Nov;25(7):572-5
pubmed: 20841345
Sci Rep. 2018 Nov 15;8(1):16866
pubmed: 30442917
Mol Aspects Med. 2005 Aug-Oct;26(4-5):235-44
pubmed: 16125765
Clin Sci (Lond). 2016 Apr;130(8):565-74
pubmed: 26957644
Front Neurol. 2022 Sep 01;13:976101
pubmed: 36119683
J Neurol. 2022 Nov;269(11):5798-5811
pubmed: 35900586
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970

Auteurs

Joung Eun Kim (JE)

Department of Family Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Hyo Sang Lee (HS)

Department of Nuclear Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.

Wooyoung Jang (W)

Department of Neurology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.

Classifications MeSH